Business Overview: Aytu BioPharma, Inc. (NASDAQ: AYTU)

---

Executive Summary

Aytu BioPharma, Inc. is a commercial-stage specialty pharmaceutical company focused on marketing and distributing prescription therapeutics, primarily in pediatrics and select adult specialty categories. Headquartered in Englewood, Colorado, Aytu has grown through a combination of product acquisitions, licensing deals, and corporate combinations (including a prior merger with Neos Therapeutics), assembling a portfolio anchored by attention-deficit/hyperactivity disorder (ADHD) therapies and other pediatric/specialty prescription products.

Aytu is a small-cap specialty pharma generating in the range of $60-90 million in annual revenue, operating with a lean commercial infrastructure model relative to large pharmaceutical companies, focused on niche therapeutic categories where a smaller, more targeted sales effort can still be commercially effective.

---

1. Core Business Model & How They Work

Rather than pursuing large-scale internal drug discovery, Aytu's strategy has centered on acquiring or licensing already-approved or late-stage specialty pharmaceutical products and commercializing them through a targeted sales and marketing organization focused on relevant prescriber specialties (pediatricians, child psychiatrists, and other relevant physicians).

[ Acquire/License Approved or Late-Stage Specialty Products ]
                          ➡️
[ Targeted Sales Force & Marketing to Relevant Prescriber Specialties ]
                          ➡️
[ Pharmacy Distribution & Payer/Formulary Access ]
                          ➡️
[ Prescription Revenue ]

Key Operational Drivers

1. Portfolio Built Through M&A and Licensing: Aytu's current product portfolio reflects a series of acquisitions and licensing transactions (including products gained through its merger with Neos Therapeutics) rather than internally discovered compounds, reflecting a capital-efficient, business-development-driven growth strategy.
2. Focused ADHD/Pediatric Franchise: A core part of Aytu's portfolio addresses ADHD treatment with extended-release, orally disintegrating tablet formulations designed to improve dosing convenience and compliance for pediatric patients, a differentiated formulation approach versus standard generic alternatives.
3. Lean Commercial Infrastructure: As a smaller specialty pharma, Aytu maintains a more targeted sales force than large pharmaceutical companies, focusing resources on specific prescriber specialties where its products have the clearest differentiation.
4. Diversification Across Specialty Categories: Beyond ADHD, Aytu has historically maintained products across other specialty/pediatric categories (such as pediatric nutritional and other prescription products), diversifying revenue beyond a single therapeutic area.

---

2. Product Portfolio

---

3. Competitive Landscape

                     LARGE PHARMA ADHD FRANCHISES
                                     │
        Takeda (Vyvanse legacy),     │
        Supernus, Teva/generics       │
                                     │
   NICHE FORMULATION DIFFERENTIATION ┼───────────────── BROAD PORTFOLIO/GENERIC SCALE
                                     │
              Aytu BioPharma (AYTU) — │      Large pharma and generic manufacturers
              orally disintegrating    │      compete on broader portfolio and
              tablet ADHD formulations  │      lower-cost generic alternatives

Competitors by Domain

ADHD Therapeutics

• Key Competitors: Numerous generic stimulant manufacturers, Supernus Pharmaceuticals (Qelbree and other ADHD products), and legacy branded competitors.
• Dynamics: The ADHD treatment market is highly genericized, with low-cost generic stimulants representing the majority of prescriptions by volume; Aytu's Adzenys XR-ODT and Cotempla XR-ODT compete on differentiated orally disintegrating tablet formulations aimed at patients (often children) who have difficulty swallowing pills, a real but narrow differentiation versus broad generic competition.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Differentiated formulation technology: Orally disintegrating tablet formulations for ADHD medications address a genuine pediatric compliance need not served by standard generic tablets or capsules.
• Focused prescriber relationships: A targeted sales approach to pediatricians and child psychiatrists builds relationships that support continued prescribing of Aytu's specific formulations.
• Diversified specialty portfolio: Multiple products across pediatric/specialty categories reduce dependence on any single product's performance.

Strategic Risks & Vulnerabilities

1. Intense generic competition in ADHD: The ADHD therapeutic category is dominated by low-cost generics, limiting the addressable market for any branded/differentiated product to patients specifically needing the differentiated formulation.
   • Mitigation Strategy: Continued focus on patient populations (particularly younger children) where swallowing difficulty makes the orally disintegrating tablet format clinically meaningful.
2. Reimbursement and formulary access risk: Payers often favor lower-cost generic alternatives, requiring ongoing efforts to secure favorable formulary placement for differentiated but higher-cost branded products.
3. Small-scale commercial infrastructure versus larger competitors: Aytu's lean sales force limits its reach compared to larger specialty pharma and pharmaceutical companies with more extensive commercial organizations.
4. Portfolio concentration and integration risk from M&A-driven growth: A strategy built on acquiring and integrating products/companies carries ongoing execution and integration risk.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Aytu BioPharma has assembled a niche specialty pharmaceutical portfolio anchored by differentiated ADHD formulations addressing genuine pediatric compliance needs, built through a series of acquisitions and licensing transactions rather than internal drug discovery, and commercialized through a lean, targeted sales organization.

The company's long-term strategic question is whether its differentiated orally disintegrating tablet formulations can continue carving out durable, profitable niches within an ADHD market otherwise dominated by low-cost generics, while it continues to manage a portfolio built through M&A rather than a single, organically-developed pipeline.